|
Title
|
|
|
|
The neuropsychology of normal aging and preclinical Alzheimer's disease
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Objective: A National Institute on Aging sponsored work group on preclinical Alzheimer's disease (AD) articulated the need to characterize cognitive differences between normal aging and preclinical AD. Methods: Seventy-one apolipoprotein E (APOE) epsilon 4 homozygotes, 194 epsilon 3/epsilon 4 heterozygotes, and 356 epsilon 4 noncarriers age 21 to 87 years who were cognitively healthy underwent neuropsychological testing every 2 years. Longitudinal trajectories of test scores were compared between APOE subgroups. Results: There was a significant effect of age on all cognitive domains in both APOE epsilon 4 carriers and noncarriers. A significant effect of APOE epsilon 4 gene dose was confined to the memory domain and the Dementia Rating Scale. Cross-sectional comparisons did not discriminate the groups. Conclusions: Although cognitive aging patterns are similar in APOE epsilon 4 carriers and noncarriers, preclinical AD is characterized by a significant epsilon 4 gene dose effect that impacts memory and is detectable longitudinally. Preclinical neuropsychological testing strategies should emphasize memory-sensitive measures and longitudinal design. (C) 2014 The Alzheimer's Association. All rights reserved. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Alzheimer's & dementia / Alzheimer’s Association [Chicago, Ill.] - Orlando, Fla, 2005, currens
| |
|
Publication
|
|
|
|
Orlando, Fla
:
Elsevier
,
2014
| |
|
ISSN
|
|
|
|
1552-5260
[print]
1552-5279
[online]
| |
|
DOI
|
|
|
|
10.1016/J.JALZ.2013.01.004
| |
|
Volume/pages
|
|
|
|
10
:1
(2014)
, p. 84-92
| |
|
ISI
|
|
|
|
000329559300011
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|